Related Experiment Video
Updated: May 29, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Outcome measures for outpatient hypoglycemia prevention studies
Roy W Beck1, Craig Kollman, Dongyuan Xing
1Jaeb Center for Health Research, Tampa, Florida 33647, USA. rbeck@jaeb.org
Journal of Diabetes Science and Technology
|September 2, 2011
Summary
Algorithms predict hypoglycemia using continuous glucose monitoring (CGM) data to stop insulin delivery. CGM metrics are key outcomes, especially in short studies where severe hypoglycemia events are rare.
Area of Science:
- Biomedical Engineering
- Endocrinology
- Diabetes Technology
Background:
- Developing predictive algorithms for hypoglycemia using continuous glucose monitoring (CGM) is crucial for diabetes management.
- Current systems aim to automatically discontinue insulin delivery upon predicted hypoglycemia.
- Assessing the efficacy of these systems in outpatient settings presents unique challenges.
Purpose of the Study:
- To highlight the importance of CGM-measured glycemic indices as primary outcome measures in studies evaluating predictive hypoglycemia algorithms.
- To address the limitations of using severe hypoglycemia event rates as an outcome in short-term studies.
- To discuss strategies for managing CGM inaccuracy in study design.
Main Methods:
- Utilizing algorithms with commercially available continuous glucose monitoring (CGM) devices.
- Focusing on CGM-measured glycemic indices as key efficacy outcomes.
- Designing studies to account for CGM inaccuracy through increased sample size or duration.
Main Results:
- CGM-measured glycemic indices serve as critical outcome measures for predictive hypoglycemia systems.
- In short-term studies, milder hypoglycemia detection can be variable, making it an unreliable primary outcome.
- CGM inaccuracy necessitates careful study design considerations.
Conclusions:
- CGM-measured glycemic indices are essential for evaluating the efficacy of predictive hypoglycemia algorithms.
- Study designs must accommodate CGM limitations, particularly in short-term trials focused on hypoglycemia reduction.
- Robust study methodologies are required to accurately assess these advanced diabetes management technologies.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:14SBAR II: Application of SBAR
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...